Atrial fibrillation (AF) is escalating into an epidemic throughout the world with more than a million people in the US developing the disease every year. In fact, the prevalence in the US and Europe has totalled over 14 million patients and is growing at an alarming rate.
a single procedure, in the persistent and long-standing persistent patient populations. Similar results (>80 % AF free) have been reported by other centres performing the Convergent Procedure. [23] [24] [25] [26] In fact, these results exceed results reported for either less invasive surgical or catheter ablation approaches alone. 27 Following the results seen at our centre and reported by other centres, we believe the Convergent Procedure is one of the most promising and interesting new approaches to treat AF today.
The Convergent Procedure should be adopted as an initial treatment option within any arrhythmia centre wanting to offer ablation to patients with enlarged atria and/or non-paroxysmal AF. The Convergent Procedure, a unique multidisciplinary approach, provides the following advantages differentiating it from other approaches:
1. Closed-chest epicardial access via transdiaphragmatic pericardial window:
• enhances patient recovery by avoiding damage to the intercostal nerves;
• mitigates respiratory complications by avoiding the need to deflate the lungs, especially single lung ventilation;
• reduces bleeding complications by leaving the attachments between the atrium and the pericardium intact; and
• provides direct endoscopic visibility of the posterior left atrium.
Epicardial ablation of posterior left atrium:
• silences the posterior left atrium to interrupt all known AF substrates' anatomic locations; and
• ablates the multitude of AF substrates to address the large unmet demand -namely AF patients with enlarged atria, higher CHADS 2 and non-paroxysmal types who previously had limited treatment options.
Multidisciplinary treatment fits within electrophysiology (EP)
practice requirements:
• performed as a single-setting procedure in the EP laboratory;
• allows patients to remain anticoagulated with therapeutic international normalized ratios (INRs);
• leverages the ability to create an anatomic set of epicardial transmural lesions with endocardial fine-tuning that ensures PV isolation and ablates endocardial structures not accessible epicardially;
• inserts a pericardial drain during epicardial portion to mitigate the risk of tamponade, which is the most common complication of catheter ablation; and • allows patients to be discharged 2-3 days post-procedure. Figure 3) . [15] [16] [17] The relationship between left atrial volume and disease complexity demonstrates why stand-alone catheter ablation has been most successful for paroxysmal AF, where assuring PV isolation alone has a higher probability of addressing clinical substrates without relying on additional lesions.
Catheter ablation studies that differentiated success and failure based on left atrial volume reported the average left atrial volume for patients who were deemed free from atrial arrhythmias ranged between 68 and 110 ml, while the average volume for patients in which atrial arrhythmias recurred ranged from 96 to 123 ml (see Figure 4 ). [14] [15] [16] [17] [18] [19] [20] The fine line between success and failure of standalone catheter ablation highlights a threshold at which an alternative treatment modality should be selected. The Convergent Procedure fills that void by targeting patients with enlarged left atrial sizes/ volumes and demonstrating promising single procedure outcomes. 21, 22 The ability to offer both catheter ablation and the Convergent Procedure in an arrhythmia centre is important because they target different patient populations. As stated previously, catheter ablation is effective in lone AF patients with normal left atria. The Convergent
Procedure is technically more difficult in these young patients with small atria and no risk factors that cause progressive structural remodeling. This population has a pericardium that tightly envelops the heart and reduces the pericardial space into which epicardial devices can traverse. In addition, the posterior left atrium, defined by the distance between the right and left PVs and bounded by the pericardial attachments, is incredibly small, reducing the need for posterior silencing. As such, simple PV isolation most likely addresses clinical substrates in lone, paroxysmal patients.
Conversely, the Convergent Procedure has demonstrated excellent efficacy in patients with enlarged atria in which structural remodeling has stretched the pericardium and increased the separation between the PVs, establishing a well defined cavity along the posterior left atrium. [23] [24] [25] [26] This is the population in which stand-alone catheter ablation has struggled. The Convergent Procedure provides a comprehensive, minimally invasive option for this previously untreatable population by silencing the posterior left atrium with a Cardiologists have limited ability to manage these patients, leading to a sense of hopelessness within these patients as their quality of life progressively declines. These are knowledgeable patients who know existing treatment limitations. The key to accessing this unmet market need is physician and patient education and awareness.
In summary, the Convergent Procedure should be a first-line treatment option for the persistent AF population. These patients represent a sizeable percentage of the AF population with high morbidity and mortality issues that add a significant economic burden to the healthcare system. Providing definitive, long-term treatment to this patient population may provide the greatest savings to the healthcare system. The Convergent Procedure is a promising approach that addresses the treatment needs of a difficult patient population and has the potential to reduce the burden this disease has on the healthcare economic system. Bringing in this type of programme requires full physician support and must be presented to the highest levels of the hospital where the management thinks strategically. The Convergent
Procedure represents an opportunity that aligns all stakeholder interests including physicians, patients, hospitals and healthcare payers. n
